In crowd­ed prostate can­cer mar­ket, Pfiz­er's Xtan­di notch­es third ap­proval for use in ear­li­er stage of dis­ease

Pfiz­er’s en­trenched an­dro­gen re­cep­tor in­hibitor Xtan­di has se­cured its third prostate can­cer ap­proval in a mar­ket flush with ri­vals.

On Mon­day, Pfiz­er and part­ner Astel­las …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER